title: Translating Germline Cancer Risk into Precision Prevention.
abstract: Study of the biology of tumors caused by germline mutations has led to recent paradigm-changing therapy and is driving precision prevention efforts, including immune oncology and early detection research. Here, we explore recent biologic advances that are redefining the spectrum of cancers linked to various hereditary predisposition syndromes and can be leveraged to improve personalized risk assessment and develop novel interventions to prevent or intercept cancer.
authors.affiliation: Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Matthew B
authors.initials: MB
authors.lastname: Yurgelun
authors.affiliation: QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
authors.forename: Georgia
authors.initials: G
authors.lastname: Chenevix-Trench
authors.affiliation: Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: slippman@ucsd.edu.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Lippman
mesh_terms: D000818:Animals; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000517:prevention & control*; D057285:Precision Medicine / Q000379:methods*